XML 44 R26.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Disaggregation of Revenues, Geographic Sales and Product Sales | 12 Months Ended
--- | ---
Dec. 29, 2023
Segment Reporting [Abstract] |
Disaggregation of Revenues, Geographic Sales and Product Sales | Note 17 — Disaggregation of Revenues, Geographic Sales and Product Sales In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product line. The following breaks down revenues into the following categories (in thousands):
|  | Years Ended |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Non-consignment sales |  | $ | 301,163 |  |  | $ | 264,620 |  |  | $ | 210,517 |
Consignment sales |  |  | 21,252 |  |  |  | 19,771 |  |  |  | 19,955 |
Total net sales |  | $ | 322,415 |  |  | $ | 284,391 |  |  | $ | 230,472 |
The Company markets and sells its products in more than 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales in that country exceed 10% of consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):
|  | Years Ended |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Domestic |  | $ | 17,221 |  |  | $ | 14,679 |  |  | $ | 10,095 |
Foreign: |  |  |  |  |  |  |  |  |
China(1) |  |  | 185,554 |  |  |  | 148,167 |  |  |  | 107,333 |
Japan |  |  | 38,472 |  |  |  | 43,093 |  |  |  | 40,973 |
Other(2) |  |  | 81,168 |  |  |  | 78,452 |  |  |  | 72,071 |
Total foreign sales |  |  | 305,194 |  |  |  | 269,712 |  |  |  | 220,377 |
Total net sales |  | $ | 322,415 |  |  | $ | 284,391 |  |  | $ | 230,472 |
(1) The China region includes sales into China and Hong Kong. (2) No other location individually exceeds 10% of the total net sales. 100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes the operating decisions and allocates resources based upon the consolidated operating results, therefore, the Company operates as one operating segment for financial reporting purposes. The Company’s principal product, ICLs, are used in refractive surgery. Historically the Company marketed and sold cataract IOLs and related injectors and injector parts. The Company phased out sales of such products in fiscal 2023, and it does not expect to sell any such products in fiscal 2024 or thereafter. The composition of the Company’s net sales by product line was as follows (in thousands):
|  | Years Ended |
|  | 2023 |  |  | 2022 |  |  | 2021 |
ICLs |  | $ | 319,427 |  |  | $ | 269,712 |  |  | $ | 212,905 |
Other product sales |  |  |  |  |  |  |  |  |
Cataract IOLs |  |  | 1,139 |  |  |  | 9,638 |  |  |  | 12,519 |
Other surgical products(1) |  |  | 1,849 |  |  |  | 5,041 |  |  |  | 5,048 |
Total other product sales |  |  | 2,988 |  |  |  | 14,679 |  |  |  | 17,567 |
Total net sales |  | $ | 322,415 |  |  | $ | 284,391 |  |  | $ | 230,472 |
(1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances. The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, U.S. and foreign export and import duties and tariffs, and political instability.

X
- Definition The entire disclosure for disaggregation of revenues, geographic sales and product sales. + References No definition available. + Details
Name: | staa_DisaggregationOfRevenuesGeographicSalesAndProductSalesDisclosureTextBlock
Namespace Prefix: | staa_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration